GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (FRA:XSQ) » Definitions » PS Ratio

SQI Diagnostics (FRA:XSQ) PS Ratio : 13.29 (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is SQI Diagnostics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, SQI Diagnostics's share price is €0.093. SQI Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was €0.01. Hence, SQI Diagnostics's PS Ratio for today is 13.29.

The historical rank and industry rank for SQI Diagnostics's PS Ratio or its related term are showing as below:

FRA:XSQ's PS Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 3.065
* Ranked among companies with meaningful PS Ratio only.

SQI Diagnostics's Revenue per Sharefor the three months ended in Mar. 2023 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was €0.01.

Back to Basics: PS Ratio


SQI Diagnostics PS Ratio Historical Data

The historical data trend for SQI Diagnostics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics PS Ratio Chart

SQI Diagnostics Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.00 11.82 63.75 63.33 5.48

SQI Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.33 9.41 5.48 5.71 8.13

Competitive Comparison of SQI Diagnostics's PS Ratio

For the Diagnostics & Research subindustry, SQI Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQI Diagnostics's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SQI Diagnostics's PS Ratio distribution charts can be found below:

* The bar in red indicates where SQI Diagnostics's PS Ratio falls into.



SQI Diagnostics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

SQI Diagnostics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.093/0.007
=13.29

SQI Diagnostics's Share Price of today is €0.093.
SQI Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


SQI Diagnostics  (FRA:XSQ) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


SQI Diagnostics PS Ratio Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (FRA:XSQ) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (FRA:XSQ) Headlines

No Headlines